1.730EUR+0.46%Mkt Cap: 47.18M EURP/E: —Last update: 2026-05-13
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead p…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-8.48
PEG—
P/B-25.43
P/S—
EV/EBITDA—
EV/Revenue—
EPS (TTM)-0.28
EPS (Forward)-0.21
Cash Flow & Leverage
FCF Yield-7.22%
FCF Margin—
Operating CF-6.10M EUR
CapEx (TTM)—
Net Debt/EBITDA—
Net Debt-2.53M EUR
Technical
SMA 501.781 (-2.8%)
SMA 2002.007 (-13.8%)
Beta0.63
S&P 52W Chg24.23%
Avg Vol (30d)26.07K
Avg Vol (10d)25.88K
Technical Indicators
RSI (14)47.3
MACD-0.0067
MACD Signal-0.0118
MACD Hist.+0.0052
BB Upper1.830 EUR
BB Middle1.749 EUR
BB Lower1.668 EUR
BB Width9.25%
ATR (14)0.1013 EUR
Vol Ratio (20d)0.23x
52W Range
1.22019% of range3.870
52W High3.870 EUR
52W Low1.220 EUR
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE392.28%
ROA-248.09%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity-0.01
Current Ratio2.92
Quick Ratio2.88
Book Value/Sh-0.0700 EUR
Cash/Share0.1080 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.26.50M
Float14.40M
Insiders24.99%
Institutions24.43%
Analyst Consensus
Rating—
Target (Mean)2.400 EUR
Target Range2.400 EUR – 2.400 EUR
# Analysts1
Company
Market Cap47.18M EUR
Enterprise Value40.36M EUR
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.62M EUR
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees13
Last Price1.730 EUR
CountryFI
SectorHealthcare
IndustryBiotechnology
ISIN—